Who are Epinephrine concentration of 1:500000's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epinephrine-concentration-of-1-500000.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Epinephrine concentration of 1:500000 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epinephrine concentration of 1:500000 (Epinephrine concentration of 1:500000) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Catecholamine; alpha and beta-adrenergic agonist. Area: Anesthesia; Cardiovascular; Respiratory.

phase 3 Catecholamine; alpha and beta-adrenergic agonist Alpha-1 adrenergic receptor; Alpha-2 adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor Anesthesia; Cardiovascular; Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Epinephrine concentration of 1:500000 (Epinephrine concentration of 1:500000) — Al-Azhar University. Epinephrine is a catecholamine that binds to alpha and beta adrenergic receptors, causing vasoconstriction, increased heart rate, and bronchodilation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Epinephrine concentration of 1:500000 TARGET	Epinephrine concentration of 1:500000	Al-Azhar University	phase 3	Catecholamine; alpha and beta-adrenergic agonist	Alpha-1 adrenergic receptor; Alpha-2 adrenergic receptor; Beta-1 adrenergic receptor; Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Catecholamine; alpha and beta-adrenergic agonist class)

Al-Azhar University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epinephrine concentration of 1:500000 — Competitive Intelligence Brief. https://druglandscape.com/ci/epinephrine-concentration-of-1-500000. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab